Axcella Health Inc.
AXLA evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Lead Asset:
- axa1125 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for AXLA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
axa1125 (Phase 2)
Next Catalyst
—
Tracking 2 pipeline candidates · 4 clinical trials for Axcella Health Inc..
Similar companies
Run Axcella Health Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Axcella Health Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is Axcella Health Inc.'s lead drug candidate?
Axcella Health Inc.'s most advanced tracked candidate is axa1125 (Phase 2) for NASH.
Who is the CEO of Axcella Health Inc.?
Craig R. Jalbert Craig is the chief executive officer of Axcella Health Inc. (AXLA).
What therapeutic areas does Axcella Health Inc. focus on?
Axcella Health Inc. develops therapies across Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.